Perioperative allogenic blood transfusions and the risk of endometrial cancer recurrence

To evaluate the effect of perioperative blood transfusions on the risk of recurrence of endometrial cancer.

This study is a retrospective analysis of 358 consecutive patients, without a history of other tumors, who underwent surgery for endometrial cancer between January 2000 and April 2010.

Women who did not need any transfusion (N = 331) and patients who received allogenic blood donations (N = 27) were compared in terms of risk of cancer recurrence. The surgical standard procedure included peritoneal washing for cytologic examination, total hysterectomy + bilateral adnexectomy (N = 358), and pelvic lymphadenectomy (N = 227). The two groups were homogeneous in term of age, BMI, previous abdominal surgery, type of intervention, operative time, nodal count, and hospital stay. The median (range) estimated blood loss was higher in the transfusion group, 400 mL (100–2,000 mL), than in the non-transfusion group, 150 mL (10–1,000 mL). Median (range) follow-up was 67.5 months (6–132.4 months). Blood transfusions were associated with a higher relapse rate (P = 0.0021). At multivariate analysis, administration of packed red blood cells remained independently associated with recurrence (OR 4.64; CI 95 % 1.45–14.9), as well as myometrial invasion ≥50 % (OR 2.88; CI 95 % 1.18–7.07) and stage >1 (OR 4.24; CI 95 % 1.75–10.3).

The use of allogenic blood transfusions is associated with a higher risk of recurrence. We hypothesize that this could be due to a transitory perioperative immunodepression that promotes the spread of neoplastic cells.